Chemkart India (CHEMKART) Q2 FY27's Profit Triples on a Doubling of Revenue
The chemical distributor's quarterly revenue hit ₹206 crore, with profit more than doubling year-on-year as margins improved.
Chemkart India's Q2 FY27 saw revenue double to ₹206 crore, driving a 130% surge in profit. The strong performance reflects a recovery in the chemical sector and operational scaling.
For a chemical distributor, scale is everything. Chemkart India’s second quarter delivered exactly that, with revenue doubling from a year ago to power a tripling of quarterly profit. The numbers signal the company is capturing a broad recovery in industrial demand.
Revenue for the quarter ended September 2026 was ₹206 crore, up 100% from the same period last year and 84% from the previous quarter. Profit after tax jumped 130% year-on-year to ₹23 crore. The net profit margin expanded to 11.2%, a 150 basis-point improvement from Q2 FY26.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin (%)
| Metric | CurrentQ2 FY27 | Same quarter LYQ2 FY26 |
|---|---|---|
| Period | Sep 2026 | Sep 2025 |
| Revenue (₹ Cr) | 206.0YoY +100% | 103.0 |
| Profit (₹ Cr) | 23.0YoY +130% | 10.0 |
| Net Profit Margin (%) | 11.2YoY +15% | 9.7 |
Riding a Sector-Wide Recovery
The surge aligns with a broader chemical sector rebound. According to an Equirus Capital report cited by Manufacturing Today India, the sector's median revenue grew 22% year-on-year in the first quarter of FY27. Chemkart’s performance, as reported by ALFA News, was driven by a doubling of revenue and progress on its new manufacturing unit. Management had previously noted achieving about 50% of FY26’s full-year revenue in just Q1 FY27, a momentum that clearly carried forward.
The Margin Question and Future Model
Profit growth outpaced revenue, pointing to operating leverage. The company reported a consolidated EBITDA margin of 14.3% for the first half, according to its investor presentation. This improvement comes as the company transitions from a pure trading model. A key risk, noted by Univest, is its heavy reliance on imports, which exposes it to currency and supplier volatility.
The real test is whether this trading strength can fund and transition into a higher-margin manufacturing business. Its wholly-owned subsidiary is building a nutraceutical CDMO facility in a JNPT Special Economic Zone, with commissioning targeted for 2027. As of September, ₹9.68 crore of IPO proceeds had been used for this facility, with capital work-in-progress at ₹9.57 crore.
A Cautious Institutional Backdrop
Despite the stellar quarter, institutional interest has been muted. Data from Stockfin.ai shows FII holding declined to 0.4% by Q4 FY26, while DII holding fell to 4.3%. This suggests a wait-and-see approach, likely tied to the perceived execution risk of the manufacturing foray. The stock trades at a P/E of 16.1, a significant discount to the industry average of 60.8.
Key Points
- Revenue for Q2 FY27 doubled year-on-year to ₹206 crore, while profit surged 130% to ₹23 crore.
- The performance reflects a broad recovery in the chemical sector, with the company scaling its distribution platform.
- Net profit margin expanded 150 basis points to 11.2%, indicating improved operational efficiency.
- The company is transitioning its model, with a new SEZ-based manufacturing facility slated for commissioning in 2027.
- Institutional investor holdings have declined, and the stock trades at a deep discount to the industry P/E.
Hexa Perspective
The quarter showcases Chemkart’s ability to capitalize on a cyclical upturn in chemical demand. The sharp revenue growth and margin expansion are impressive for a distribution business. However, the sustainability of this momentum is now tied to two factors: the durability of the sector recovery and the successful execution of its manufacturing pivot.
The valuation gap reflects the market’s skepticism about that transition and the capital intensity it requires. For the premium to close, Chemkart must demonstrate that its new facility can generate returns that justify the investment, moving beyond the volatile margins of trading.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.